What’s New in the 2024 CLSI Standards for Antimicrobial Susceptibility Testing?

Includes a Live Web Event on 04/17/2024 at 1:00 PM (EDT)

  • Registration Closed

Join CLSI on April 17 at 1:00 ET for a webinar on the latest in Antimicrobial Susceptibility Testing (AST) with the release of the 34th edition of the CLSI M100 document. Receive the latest guidance for implementing new breakpoints and standards into your laboratory practices. Some of the major changes that will be discussed during the webinar include a significant reorganization of dosage recommendations, addition of sulbactam-durlobactam to breakpoints, a new Table 2A-2 for Salmonella and Shigella, and many more. A few substantive changes to the upcoming CLSI M02 and M07 will also be discussed.

Learning Objectives:

1. Identify the major changes found in the updated 34th edition of the CLSI M100 document.
2. Design a strategy for implementing the new standard into laboratory practices.
3. Develop a communication strategy for informing clinical staff of significant AST and reporting changes

Register for the webinar to watch live on April 17, 2024 at 1 PM ET | 12 PM CT | 11 AM MT | 10 AM PT
Or watch the webinar on-demand anytime. The on-demand recording will be available on April 19, 2024. 

CLSI is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

Janet Hindler, MCLS, MT(ASCP), F(AAM) (Moderator)

Clinical Microbiologist

Los Angeles County Department of Public Health

Ms. Hindler has worked as a clinical microbiologist for over 5 decades, mostly at UCLA Health System, Los Angeles, CA and currently at the Los Angeles County Department of Public Health. She is a fellow in the American Academy of Microbiology and long-standing volunteer with the CLSI Subcommittee on Antimicrobial Susceptibility Testing (AST). She has authored or co-authored numerous publications and book chapters and has received many awards for her contributions to AST and clinical microbiology.

April Bobenchik, PhD, D(ABMM)

Medical Director Microbiology and Associate Professor

Penn State Health and College of Medicine

Dr. Bobenchik is a board-certified clinical microbiologist with over 20 years of experience working in the laboratory. She is currently the Medical Director of Microbiology and Virology at Penn State Hershey Medical Center and Associate Professor of Pathology at Penn State College of Medicine. She has been a volunteer with CLSI since 2013 and is the current co-chair of the text and table working group and a member of the outreach working group.

Romney Humphries, PhD D(ABMM)

Professor, Department of Pathology, Microbiology and Immunology

Vanderbilt University Medical Center

Romney Humphries, PhD D(ABMM) is a Professor in the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, where she is the Director of Infectious Diseases Laboratories and the Director of the Division of Laboratory Medicine. Romney received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA.

Dr. Humphries is passionate about clinical microbiology and antimicrobial resistance in particular. She is a champion for the development of novel diagnostic tests for infectious diseases to transform how patients with infections are managed.

Key:

Complete
Failed
Available
Locked
What’s New in the 2024 CLSI Standards for Antimicrobial Susceptibility Testing?
04/17/2024 at 1:00 PM (EDT)  |  90 minutes
04/17/2024 at 1:00 PM (EDT)  |  90 minutes